App-Quantinova.ai

Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit

Hannah Cooney - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Exploratory Analysis of Filgotinib Safety Data in Patients With Moderately to Severely Active Rheumatoid arthritis and an Increased Risk of Cardiovascular Events: Data From Phase 2 and 3 Clinical Trials

Maya H Buch - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Peripheral artery disease

Filgotinib

Patient Experience of Remote Healthcare during the Pandemic in Rheumatoid Arthritis and Adult Juvenile Idiopathic Arthritis

Rajinder S Andev - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Attitudes to Technology supported Rheumatoid Arthritis care Questionnaire study: Barriers to People with RA & their clinicians using Technology in the care pathway

Amy MacBrayne - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Exploring micro-RNA content of circulating extracellular vesicles as biomarkers in early rheumatoid arthritis

Daniel Maunder - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Methotrexate

Healthcare professionals' perspectives on integrating predictive and emerging preventive approaches in rheumatoid arthritis care: A qualitative investigation

Gwenda Simons - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Systematic review of the prevalence of foot disease activity in patients classed in disease activity score-28 remission

Kirsty McIlwaine - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Machine-learning derived characteristics associated with tapering TNF inhibitors in individuals with rheumatoid arthritis

Thomas Phillips - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Baseline Characteristics of and Early Outcomes in the First 200 Patients With Rheumatoid arthritis Treated With Filgotinib in a Prospective Observational Study

James Galloway - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Filgotinib

The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in Rheumatoid Arthritis

Patrick Durez - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Filgotinib

What's driving this disease activity score? A support framework to aid your decision

Brian Rhys-Dillion - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Biologic dose tapering: a patient perspective

Rayan Rahman - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Certolizumab pegol

Rheumatoid Arthritis with Normal CRP: an Underappreciated, Persistent Phenotype: Equally at Risk of Severe Disease

Matthew Hutchinson - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Long-term efficacy of baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from RA-BEYOND up to 7 years of treatment

Roberto Caporali - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

Cycling of JAK inhibitors: Experience from a large UK teaching hospital

Eavan M Quinlan - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials

Bruce W Kirkham - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

DNA methylation of the tumour necrosis factor gene as a biomarker of diagnosis in early rheumatoid arthritis patients

Melanie C Liu - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Transcriptomic analysis of synovitis identifies inhibition of CXCL1 as a mechanism contributing to resolution of inflammatory arthritis under IL-27 control

Isabel Burridge - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Interferon Gamma

A late and rapid increase in ultrasound joint inflammation occurs when anti-CCP positive at-risk individuals with subclinical synovitis progress to inflammatory arthritis

Kate Harnden - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Orphenadrine Citrate

Attitudes to Technology supported Rheumatoid Arthritis care: Opportunities & Barriers for technology in RA - Key themes from Qualitative arm of Mixed-Methods Study

Amy MacBrayne - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Filters

45280 Abstracts